Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Liver cancer

Time to evolve trial design after everolimus failure

Nature Reviews Clinical Oncology volume 11, pages 506–507 (2014)Cite this article

Subjects

Hepatocellular carcinoma is a difficult-to-treat cancer and, after numerous phase III trials assessing kinase inhibitors have failed to meet their end points, sorafenib is the only accepted treatment for advanced stages of the disease. Now, the trial EVOLVE-1 has shown a lack of benefit for everolimus in the second-line treatment setting.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. European Association for the Study of the Liver and European Association for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908–943 (2012).

  2. Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet 379, 1245–1255 (2012).

    PubMed  Google Scholar 

  3. Llovet, J. M. & Bruix, J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37, 429–442 (2003).

    Article  CAS  PubMed  Google Scholar 

  4. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).

    Article  CAS  PubMed  Google Scholar 

  5. Llovet, J. M. & Hernández-Gea, V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin. Cancer Res. 20, 2072–2079 (2014).

    Article  CAS  PubMed  Google Scholar 

  6. Villanueva, A. et al. Pivotal role of mTOR signaling in HCC. Gastroenterology 135, 1972–1983 (2008).

    Article  PubMed  CAS  Google Scholar 

  7. Zhu, A. et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib. JAMA 312, 57–67 (2014).

    Article  PubMed  Google Scholar 

  8. Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693–1703 (2010).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Farazi, P A. & DePinho, R. A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6, 674–687 (2006).

    Article  CAS  PubMed  Google Scholar 

  10. Villanueva, A. & Llovet, J. M. Liver cancer in 2013: Mutational landscape of HCC-end of the beginning. Nat. Rev. Clin. Oncol. 11, 73–74 (2014).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

J.M.L. is supported by grants from the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (1R01DK076986-01), European Commission-FP7 Framework (HEPTROMIC, Proposal No: 259,744), the Asociación Española Contra el Cáncer, the Samuel Waxman Cancer Research Foundation and the Spanish National Health Institute (SAF-2010-16055).

Author information

Authors and Affiliations

  1. HCC Translational Research Laboratory, BCLC Group, Liver Unit, IDIBAPS, CIBERehd, Hospital Clínic, University of Barcelona, Institució Catalana de Recerca i Estudis Avançats, Rosselló 153, Barcelona, 08036, Spain

    Josep M. Llovet

Authors
  1. Josep M. Llovet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Josep M. Llovet.

Ethics declarations

Competing interests

J.M.L. is a consultant for Bayer Pharmaceuticals, Blueprint, Boeringher-Ingelheim, Bristol–Myers Squibb, Celsion, Imclone-Lilly, Novartis, and provides research support for Bayer Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Llovet, J. Time to evolve trial design after everolimus failure. Nat Rev Clin Oncol 11, 506–507 (2014). https://doi.org/10.1038/nrclinonc.2014.136

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2014.136

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing